A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC)

W. Schröder,M Campone,S. Abadie,P. Witteveen,P. Viens,T Jalava,M. Palacay-Radona,S. Bilic,D. Laurent,A du Bois

A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC)

2005

W. Schröder
M Campone
S. Abadie
P. Witteveen
P. Viens
T Jalava
M. Palacay-Radona
S. Bilic
D. Laurent
A du Bois

5042 Background: PTK787/ZK 222584 (PTK/ZK) is a novel, oral, small molecule, anti-angiogenisis compound that blocks tyrosine kinase signaling from all known vascular endothelial growth factor VEGF ...

Keywords:

Pathology
Carboplatin
Ovarian cancer
Paclitaxel
Cancer research
Pharmacokinetics
Medicine
Tyrosine kinase
Vascular endothelial growth factor
open label
Small molecule
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations